Cover Image
市場調查報告書

便秘:開發平台分析

Constipation - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192536
出版日期 內容資訊 英文 108 Pages
訂單完成後即時交付
價格
Back to Top
便秘:開發平台分析 Constipation - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 108 Pages
簡介

便秘,在排便困難或頻率少的情況發生。便秘的症狀有腹部的膨脹或腹痛,疼痛及嘔吐等。原因包含有飲食障礙、大腸躁鬱症、甲狀腺機能低下症、便秘藥過量使用、過勞、腸肌肉的衰弱、緊張狀態、水分的攝取不足、飲食的纖維不足等。治療有便秘藥的使用與恰當的生活方式。

本報告以全球便秘治療藥的開發平台為主題,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

便秘概要

治療藥的開發

  • 便秘開發中產品:概要
  • 便秘開發中產品:比較分析

便秘:正在開發的治療藥 - 各企業

便秘:正在開發的治療藥 - 各大學、研究機關

便秘:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

便秘:開發中的產品 - 各企業

便秘:開發中的產品 - 各大學、研究機關

便秘:開發治療藥的企業

  • AlbireoPharma
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • Braintree Laboratories, Inc.
  • CJ HealthCare Corp.
  • 第一三共
  • Ironwood Pharmaceuticals, Inc.
  • Kissei藥品工業
  • NGM Biopharmaceuticals, Inc.
  • RaQualia Pharma Inc.
  • Rhythm Pharmaceuticals, Inc.
  • 三和化學研究所
  • Shire Plc
  • SK Biopharmaceuticals Co., Ltd.
  • Sucampo Pharmaceuticals, Inc.
  • 大日本住友製藥
  • Synergy Pharmaceuticals, Inc.
  • Synthetic Biologics, Inc.
  • Yuhan Corporation

便秘:治療藥的評估

  • 單劑治療藥
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ASP-7663
    • 產品概要
    • 作用機制
    • R&D的進展
  • BLI-400
  • DA-6886
  • DS-3801
  • DSP-6952
  • elobixibat
  • KWA-0711
  • linaclotide
  • lubiprostone
  • NGM-282
  • plecanatide
  • prucalopride succinate
  • relamorelin
  • relenopride hydrochloride
  • RQ-00000010
  • SK-1202
  • 便秘、消化不良治療用5-HT1受體活性小分子
  • 慢性便秘、大腸躁鬱症治療用 IBAT 抑制劑
  • SYN-010
  • tenapanor hydrochloride
  • Transilon
  • YH-12852

最新的開發平台趨勢

暫停中的計劃

產品開發里程碑

  • 注目新聞、新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8966IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H1 2017, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.

Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Constipation - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 7, 8, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Constipation - Overview
  • Constipation - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Constipation - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Constipation - Companies Involved in Therapeutics Development
    • Albireo Pharma Inc
    • Ardelyx Inc
    • Assembly Biosciences Inc
    • Astellas Pharma Inc
    • Braintree Laboratories Inc
    • CJ HealthCare Corp
    • Dong-A Socio Holdings Co Ltd
    • EA Pharma Co Ltd
    • Ironwood Pharmaceuticals Inc
    • Lipid Pharmaceuticals ehf
    • Motus Therapeutics Inc
    • NGM Biopharmaceuticals Inc
    • RaQualia Pharma Inc
    • Sanwa Kagaku Kenkyusho Co Ltd
    • Shire Plc
    • SK Biopharmaceuticals Co Ltd
    • Sucampo Pharmaceuticals Inc
    • Sumitomo Dainippon Pharma Co Ltd
    • Synthetic Biologics Inc
    • Torrent Pharmaceuticals Ltd
    • Yuhan Corp
  • Constipation - Drug Profiles
    • 5-BIOP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AJG-555 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-7663 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLI-400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLI-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CJ-14199 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DA-6886 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-6952 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elobixibat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • J-027 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • linaclotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lovastatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lubiprostone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naronapride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NGM-282 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • prucalopride succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • prucalopride succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relamorelin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relenopride hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00000010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SK-1202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tenapanor hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-12852 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Constipation - Dormant Projects
  • Constipation - Product Development Milestones
    • Featured News & Press Releases
      • Feb 01, 2017: Albireo Announces Submission of New Drug Application for Elobixibat in Japan
      • Jan 30, 2017: Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
      • Jan 26, 2017: U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS (linaclotide) for Adults with Chronic Idiopathic Constipation
      • Dec 22, 2016: Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C
      • Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride
      • Oct 19, 2016: Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting
      • Oct 03, 2016: Albireo Announces Positive Top-Line Phase 3 Results for Elobixibat in Japan
      • Sep 30, 2016: EA Pharma and Mochida Pharmaceutical Announce the Results of Phase 3 Study of AJG533 for Chronic Constipation Conducted in Japan
      • Aug 19, 2016: The First Dosing of RQ-00000010 at Virginia Commonwealth University Initiated
      • Aug 02, 2016: Synthetic Biologics Announces Completion of End of Phase 2 Meeting with FDA for SYN-010, Intended for the Treatment of Irritable Bowel Syndrome with Constipation
      • Jun 09, 2016: Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
      • May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
      • May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016
      • May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
      • May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Constipation, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Constipation - Pipeline by Albireo Pharma Inc, H1 2017
  • Constipation - Pipeline by Ardelyx Inc, H1 2017
  • Constipation - Pipeline by Assembly Biosciences Inc, H1 2017
  • Constipation - Pipeline by Astellas Pharma Inc, H1 2017
  • Constipation - Pipeline by Braintree Laboratories Inc, H1 2017
  • Constipation - Pipeline by CJ HealthCare Corp, H1 2017
  • Constipation - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
  • Constipation - Pipeline by EA Pharma Co Ltd, H1 2017
  • Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
  • Constipation - Pipeline by Lipid Pharmaceuticals ehf, H1 2017
  • Constipation - Pipeline by Motus Therapeutics Inc, H1 2017
  • Constipation - Pipeline by NGM Biopharmaceuticals Inc, H1 2017
  • Constipation - Pipeline by RaQualia Pharma Inc, H1 2017
  • Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2017
  • Constipation - Pipeline by Shire Plc, H1 2017
  • Constipation - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
  • Constipation - Pipeline by Sucampo Pharmaceuticals Inc, H1 2017
  • Constipation - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Constipation - Pipeline by Synthetic Biologics Inc, H1 2017
  • Constipation - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
  • Constipation - Pipeline by Yuhan Corp, H1 2017
  • Constipation - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Constipation, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top